 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Enrollment change, Trial completion date, Trial primary completion date, Metastases: TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov) - Jul 12, 2024
P3, N=190, Recruiting, Sponsor: RenovoRx
N=320 --> 190 | Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Jun 2026
- ||| RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Clinical: .@MPishvaian, TIGeR-PaC study PI, discusses the positive Ph. III interim analysis data which demonstrated an 8-month median PFS benefit in delaying the progression of #LAPC for patients receiving treatment with RenovoGem vs standard-of-care. https://t.co/pUnA4Tg21H $RNXT @OncLive (Twitter) - Jun 30, 2023
- RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Intra-arterial gemcitabine vs IV gemcitabine PK substudy in patients with locally advanced pancreatic cancer. (Available On Demand; Poster Board No. L15) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_585;
P3
This approach increased local potency and may be beneficial in decreasing gemcitabine-related systemic side effects. 1.
- || RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Trial completion, Phase classification: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - May 7, 2021
P1, N=20, Completed, Sponsor: RenovoRx
1. Active, not recruiting --> Completed | Phase classification: P4 --> P1
- || RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Phase classification, Metastases: TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov) - Apr 24, 2019
P3, N=300, Recruiting, Sponsor: RenovoRx
Active, not recruiting --> Completed | Phase classification: P4 --> P1 Phase classification: P4 --> P3
- ||| RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Enrollment change, Metastases: TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov) - Jun 6, 2018
P4, N=300, Recruiting, Sponsor: RenovoRx
Phase classification: P4 --> P3 N=200 --> 300
- |||| RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Enrollment open, Trial completion date, Trial primary completion date, Metastases: TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov) - Apr 11, 2018
P4, N=200, Recruiting, Sponsor: RenovoRx
N=200 --> 300 Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2022
- ||| RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Trial initiation date, Metastases: TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov) - Feb 22, 2018
P4, N=200, Not yet recruiting, Sponsor: RenovoRx
Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2022 Initiation date: Sep 2017 --> Feb 2018
- ||||| RenovoGem (gemcitabine with RenovoCath) / RenovoRx
New P4 trial, Metastases: TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov) - Aug 21, 2017
P4, N=200, Not yet recruiting, Sponsor: RenovoRx
- | RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Enrollment closed: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Mar 24, 2016
P4, N=20, Active, not recruiting, Sponsor: RenovoRx
Initiation date: Sep 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Trial primary completion date: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Feb 10, 2016
P4, N=20, Recruiting, Sponsor: RenovoRx
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Jul 2016
- RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Enrollment open: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Mar 10, 2015
P4, N=20, Recruiting, Sponsor: RenovoRx
Trial primary completion date: Jan 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Phase classification, Trial initiation date: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Feb 6, 2015
P4, N=20, Not yet recruiting, Sponsor: RenovoRx
Not yet recruiting --> Recruiting Phase classification: P1 --> P4 | Initiation date: Nov 2014 --> Feb 2015
- RenovoGem (gemcitabine with RenovoCath) / RenovoRx
New P1 trial: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer (clinicaltrials.gov) - Sep 11, 2014
P1, N=20, Not yet recruiting, Sponsor: RenovoRx